Clinical trials are currently evaluating the response of HNSCC patients to single or dual targeted therapy treatments, such as EGFR (NCT02365662) or PI3K (NCT02145312, NCT02540928) monotherapies or both agents administered in combination (NCT0160231). The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.